Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) announced on November 16, 2026, that it has entered into an underwriting agreement with Lake Street Capital Markets, LLC to sell shares of its common stock. The offering includes 8,296,429 shares of common stock and pre-funded warrants to purchase up to 275,000 shares of common stock. The shares are being sold at a public offering price of $1.75 per share, while the pre-funded warrants are priced at $1.7499 per warrant.

The company also granted the underwriter a 30-day option to purchase up to an additional 1,285,714 shares of common stock at the public offering price, subject to customary closing conditions. The offering is expected to close on or about November 18, 2026.

Insight Molecular Diagnostics intends to use the net proceeds from the offering for working capital and general corporate purposes, including research and development in the transplantation category. The offering is being made pursuant to a registration statement on Form S-3 (File No. 333-281159) that was declared effective by the SEC on August 7, 2024.